These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 32858021)

  • 1. Nephrolithiasis from an Unexpected Cause: Phosphaturia.
    Patel AB; Verma A; McMahon GM
    Am J Med; 2021 Feb; 134(2):e131-e132. PubMed ID: 32858021
    [No Abstract]   [Full Text] [Related]  

  • 2. Increase in phosphaturia by inhibition of renal sodium-dependent phosphate cotransporter NPT2a.
    Drueke TB
    Kidney Int; 2021 Mar; 99(3):533-536. PubMed ID: 33069763
    [No Abstract]   [Full Text] [Related]  

  • 3. Phosphaturic action of fibroblast growth factor 23 in Npt2 null mice.
    Tomoe Y; Segawa H; Shiozawa K; Kaneko I; Tominaga R; Hanabusa E; Aranami F; Furutani J; Kuwahara S; Tatsumi S; Matsumoto M; Ito M; Miyamoto K
    Am J Physiol Renal Physiol; 2010 Jun; 298(6):F1341-50. PubMed ID: 20357029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Akt2/PKBbeta-sensitive regulation of renal phosphate transport.
    Kempe DS; Ackermann TF; Boini KM; Klaus F; Umbach AT; Dërmaku-Sopjani M; Judenhofer MS; Pichler BJ; Capuano P; Stange G; Wagner CA; Birnbaum MJ; Pearce D; Föller M; Lang F
    Acta Physiol (Oxf); 2010 Sep; 200(1):75-85. PubMed ID: 20236253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel phosphate-regulating genes in the pathogenesis of renal phosphate wasting disorders.
    Tenenhouse HS; Sabbagh Y
    Pflugers Arch; 2002 Jun; 444(3):317-26. PubMed ID: 12111239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, biochemical, and pathophysiological analysis of SLC34A1 mutations.
    Fearn A; Allison B; Rice SJ; Edwards N; Halbritter J; Bourgeois S; Pastor-Arroyo EM; Hildebrandt F; Tasic V; Wagner CA; Hernando N; Sayer JA; Werner A
    Physiol Rep; 2018 Jun; 6(12):e13715. PubMed ID: 29924459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin-induced phosphaturia.
    Kempe DS; Dërmaku-Sopjani M; Fröhlich H; Sopjani M; Umbach A; Puchchakayala G; Capasso A; Weiss F; Stübs M; Föller M; Lang F
    Nephrol Dial Transplant; 2010 Sep; 25(9):2938-44. PubMed ID: 20368307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic disorders of renal phosphate transport.
    Levtchenko E; Schoeber J; Jaeken J
    N Engl J Med; 2010 Oct; 363(18):1774; author reply 1774-5. PubMed ID: 21038516
    [No Abstract]   [Full Text] [Related]  

  • 9. Rare Cause of Infantile Hypercalcemia: A Novel Mutation in the SLC34A1 Gene.
    Kurnaz E; Savaş Erdeve Ş; Çetinkaya S; Aycan Z
    Horm Res Paediatr; 2019; 91(4):278-284. PubMed ID: 30227399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal phosphate handling and inherited disorders of phosphate reabsorption: an update.
    Wagner CA; Rubio-Aliaga I; Hernando N
    Pediatr Nephrol; 2019 Apr; 34(4):549-559. PubMed ID: 29275531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiopathic calcium nephrolithiasis: a review of pathogenic mechanisms in the light of genetic studies.
    Arcidiacono T; Mingione A; Macrina L; Pivari F; Soldati L; Vezzoli G
    Am J Nephrol; 2014; 40(6):499-506. PubMed ID: 25504362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. X-linked hypophosphatemia. Genetic and clinical correlates.
    Hanna JD; Niimi K; Chan JC
    Am J Dis Child; 1991 Aug; 145(8):865-70. PubMed ID: 1858722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of phosphonoformic acid and renagel on renal type IIa sodium-dependent phosphate cotransporter mRNA expression in hyperphosphatemia rats.
    Zeng M; Wang X; Wang X; Zhao X
    Ren Fail; 2012; 34(3):358-63. PubMed ID: 22260362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinico-genetic considerations on a case of hypophosphatemia associated with epilepsy].
    Truşcă E; Dumitrescu T; Telea N; Truşcă E
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1974; 19(4):361-8. PubMed ID: 4377620
    [No Abstract]   [Full Text] [Related]  

  • 15. Fibroblast growth factor-23 and outcomes: new answers, new questions.
    Bhan I; Thadhani R
    J Am Soc Nephrol; 2013 Mar; 24(4):523-5. PubMed ID: 23520207
    [No Abstract]   [Full Text] [Related]  

  • 16. [Phosphate diabetes due to familial proximal tubulopathy].
    Laroche M; Arlet J; Ader JL; Tran Van T; Mazières B
    Presse Med; 1990 Oct; 19(34):1587. PubMed ID: 2147243
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral phosphate supplements reverse skeletal muscle abnormalities in a case of chronic fatigue with idiopathic renal hypophosphatemia.
    Land JM; Kemp GJ; Taylor DJ; Standing SJ; Radda GK; Rajagopalan B
    Neuromuscul Disord; 1993 May; 3(3):223-5. PubMed ID: 8400863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies of calcium phosphate metabolism in a case of McCune-Albright syndrome with phosphate diabetes (author's transl)].
    Grubbauer HM; Stögmann W; Messner H
    Z Kinderheilkd; 1974 Apr; 117(1):47-61. PubMed ID: 4365131
    [No Abstract]   [Full Text] [Related]  

  • 19. [Fibroblast growth factor 23 mediates the phosphaturic actions of cadmium].
    Kido S; Fujihara M; Nomura K; Sasaki S; Shiozaki Y; Segawa H; Tatsumi S; Miyamoto K
    Nihon Eiseigaku Zasshi; 2012; 67(4):464-71. PubMed ID: 23095356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological Npt2a Inhibition Causes Phosphaturia and Reduces Plasma Phosphate in Mice with Normal and Reduced Kidney Function.
    Thomas L; Xue J; Murali SK; Fenton RA; Dominguez Rieg JA; Rieg T
    J Am Soc Nephrol; 2019 Nov; 30(11):2128-2139. PubMed ID: 31409727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.